Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target [Yahoo! Finance]
Biomea Fusion, Inc. (BMEA)
Company Research
Source: Yahoo! Finance
In Q3 2025, Biomea announced that the company was shifting its strategy to focus on its two primary assets: icovamenib, a menin inhibitor for type 2 diabetes/T2D, and BMF-650, an oral GLP-1 receptor agonist for obesity. Icovamenib is an oral small molecule designed to partially inhibit menin, a protein that acts as a brake on pancreatic beta-cell growth. By inhibiting menin, the therapy aims to regenerate and reactivate healthy, insulin-producing beta cells, potentially offering a disease-modifying treatment for diabetes rather than just managing symptoms. During the quarter, Biomea Fusion Inc. (NASDAQ:BMEA) reported durable 52-week data from its Phase II COVALENT-111 study. In patients with severe insulin-deficient T2D, a short 12-week course of icovamenib resulted in a sustained 1.5% mean reduction in HbA1c nine months after dosing ended. Additionally, patients who had failed to reach glycemic targets on GLP-1 therapies saw a 1.3% reduction in HbA1c. These results are particularl
Show less
Read more
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion (NASDAQ:BMEA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $12.00 price target on the stock.MarketBeat
- Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 MilestonesGlobeNewswire
- Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
BMEA
Earnings
- 11/4/25 - Miss
BMEA
Sec Filings
- 1/14/26 - Form 8-K
- 1/6/26 - Form S-8
- 12/15/25 - Form 4
- BMEA's page on the SEC website